Scynexis announced that the FDA has designated SCY-078 a Qualified Infectious Disease Product (QDIP) for the treatment of invasive Candidiasis, including Candidemia and  Aspergillosis. SCY-078 (formerly MK-3118), a semi-synthetic derivative of the natural product enfumafungin is an oral glucan synthase inhibitor.

Glucan synthase inhibitors have been effective in treating invasive fungal infections in a hospital setting but are currently only available in intravenous formulations. Multiple Phase 1 studies have been completed on this novel compound.

RELATED: Infectious Disease Resource Center

SCY-078 is currently entering into Phase 2 trials and has shown activity against the two main pathogens responsible for the majority of invasive fungal infections (IFI), Candida and Aspergillus species.

For more information call (919) 544-8600 or visit